Aligos Therapeutics Stock Net Income
| ALGS Stock | USD 8.59 0.20 2.38% |
As of the 28th of January, Aligos Therapeutics shows the Standard Deviation of 5.7, mean deviation of 4.52, and Risk Adjusted Performance of 0.0026. Aligos Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aligos Therapeutics coefficient of variation and maximum drawdown to decide if Aligos Therapeutics is priced correctly, providing market reflects its regular price of 8.59 per share. Given that Aligos Therapeutics has information ratio of (0.02), we suggest you to validate Aligos Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.
Aligos Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.3833 | Revenue | Earnings Share (13.54) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -118.1 M | -124 M | |
| Net Loss | -86.4 M | -90.8 M | |
| Net Loss | -118.1 M | -124 M | |
| Net Loss | (24.09) | (22.88) | |
| Net Income Per E B T | 0.90 | 0.80 |
Aligos | Net Income | Build AI portfolio with Aligos Stock |
Latest Aligos Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Aligos Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aligos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aligos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aligos Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (131.21 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aligos Net Income Regression Statistics
| Arithmetic Mean | (57,150,370) | |
| Coefficient Of Variation | (88.20) | |
| Mean Deviation | 46,334,436 | |
| Median | (13,933,000) | |
| Standard Deviation | 50,406,577 | |
| Sample Variance | 2540.8T | |
| Range | 117.3M | |
| R-Value | (0.88) | |
| Mean Square Error | 614.6T | |
| R-Squared | 0.77 | |
| Slope | (8,777,420) | |
| Total Sum of Squares | 40653.2T |
Aligos Net Income History
Other Fundumenentals of Aligos Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Aligos Therapeutics Net Income component correlations
Aligos Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aligos Therapeutics is extremely important. It helps to project a fair market value of Aligos Stock properly, considering its historical fundamentals such as Net Income. Since Aligos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aligos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aligos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aligos Therapeutics. If investors know Aligos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aligos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.54) | Revenue Per Share | Quarterly Revenue Growth (0.42) | Return On Assets | Return On Equity |
The market value of Aligos Therapeutics is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aligos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos Therapeutics' market value can be influenced by many factors that don't directly affect Aligos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aligos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aligos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aligos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aligos Therapeutics.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Aligos Therapeutics on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Aligos Therapeutics or generate 0.0% return on investment in Aligos Therapeutics over 90 days. Aligos Therapeutics is related to or competes with Kezar Life, X4 Pharmaceuticals, Tempest Therapeutics, Barinthus Biotherapeutics, OnKure Therapeutics, CEL SCI, and INmune Bio. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address ... More
Aligos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aligos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aligos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 28.43 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 10.16 |
Aligos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aligos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aligos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aligos Therapeutics historical prices to predict the future Aligos Therapeutics' volatility.| Risk Adjusted Performance | 0.0026 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | 0.2976 |
Aligos Therapeutics January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0026 | |||
| Market Risk Adjusted Performance | 0.3076 | |||
| Mean Deviation | 4.52 | |||
| Coefficient Of Variation | (12,103) | |||
| Standard Deviation | 5.7 | |||
| Variance | 32.52 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.59) | |||
| Treynor Ratio | 0.2976 | |||
| Maximum Drawdown | 28.43 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 10.16 | |||
| Skewness | 0.3926 | |||
| Kurtosis | 0.1513 |
Aligos Therapeutics Backtested Returns
Aligos Therapeutics appears to be moderately volatile, given 3 months investment horizon. Aligos Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0416, which signifies that the company had a 0.0416 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Aligos Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Aligos Therapeutics' Risk Adjusted Performance of 0.0026, standard deviation of 5.7, and Mean Deviation of 4.52 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Aligos Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of -0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Aligos Therapeutics are expected to decrease at a much lower rate. During the bear market, Aligos Therapeutics is likely to outperform the market. Please check Aligos Therapeutics' maximum drawdown, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Aligos Therapeutics' price patterns will revert.
Auto-correlation | -0.56 |
Good reverse predictability
Aligos Therapeutics has good reverse predictability. Overlapping area represents the amount of predictability between Aligos Therapeutics time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aligos Therapeutics price movement. The serial correlation of -0.56 indicates that roughly 56.0% of current Aligos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.56 | |
| Spearman Rank Test | -0.74 | |
| Residual Average | 0.0 | |
| Price Variance | 1.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aligos Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Aligos Therapeutics reported net income of (131.21 Million). This is 138.45% lower than that of the Biotechnology sector and 287.32% lower than that of the Health Care industry. The net income for all United States stocks is 122.98% higher than that of the company.
Aligos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aligos Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aligos Therapeutics could also be used in its relative valuation, which is a method of valuing Aligos Therapeutics by comparing valuation metrics of similar companies.Aligos Therapeutics is currently under evaluation in net income category among its peers.
Aligos Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aligos Therapeutics from analyzing Aligos Therapeutics' financial statements. These drivers represent accounts that assess Aligos Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aligos Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 11.8B | 1.0B | 412.9M | 249.6M | 287.0M | 272.7M | |
| Enterprise Value | 11.7B | 948.2M | 288.3M | 221.0M | 254.1M | 241.4M |
Aligos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aligos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aligos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aligos Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aligos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aligos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aligos Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 34 K | Lpl Financial Corp | 2025-06-30 | 30.1 K | Charles Schwab Investment Management Inc | 2025-06-30 | 25.4 K | Squarepoint Ops Llc | 2025-06-30 | 18.6 K | Citadel Advisors Llc | 2025-06-30 | 15.2 K | Xtx Topco Ltd | 2025-06-30 | 13.8 K | Wells Fargo & Co | 2025-06-30 | 13.8 K | Blackrock Inc | 2025-06-30 | 13 K | Millennium Management Llc | 2025-06-30 | 12.3 K | Woodline Partners Lp | 2025-06-30 | 518.3 K | Deep Track Capital, Lp | 2025-06-30 | 444.1 K |
Aligos Fundamentals
| Return On Equity | -1.42 | ||||
| Return On Asset | -0.55 | ||||
| Operating Margin | (38.27) % | ||||
| Current Valuation | (43.06 M) | ||||
| Shares Outstanding | 5.35 M | ||||
| Shares Owned By Insiders | 10.36 % | ||||
| Shares Owned By Institutions | 53.10 % | ||||
| Number Of Shares Shorted | 240.69 K | ||||
| Price To Book | 0.70 X | ||||
| Price To Sales | 19.51 X | ||||
| Revenue | 3.94 M | ||||
| Gross Profit | (65.8 M) | ||||
| EBITDA | (86.53 M) | ||||
| Net Income | (131.21 M) | ||||
| Cash And Equivalents | 159.34 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 8.38 M | ||||
| Debt To Equity | 0.1 % | ||||
| Current Ratio | 5.30 X | ||||
| Book Value Per Share | 11.67 X | ||||
| Cash Flow From Operations | (80.74 M) | ||||
| Short Ratio | 3.39 X | ||||
| Earnings Per Share | (13.54) X | ||||
| Target Price | 68.2 | ||||
| Number Of Employees | 70 | ||||
| Beta | 2.65 | ||||
| Market Capitalization | 51.63 M | ||||
| Total Asset | 70.09 M | ||||
| Retained Earnings | (618.01 M) | ||||
| Working Capital | 40.4 M | ||||
| Net Asset | 70.09 M |
About Aligos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aligos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aligos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aligos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.